[Biosimilar: can we manage biopharmaceutical heterogeneity?].
Ranieri
Elena
E
Cattedra di Patologia Clinica, Dipartimento di Scienze Biomediche, Università degli Studi, Foggia, Italy. e.raneiri@unifg.it
D001688:Biological Products / Q000009:adverse effects / Q000096:biosynthesis / Q000494:pharmacology / Q000627:therapeutic use*; D001709:Biotechnology / Q000331:legislation & jurisprudence / Q000639:trends; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical; D016568:Drugs, Generic; D005060:Europe; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000276:immunology; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000096:biosynthesis; D013810:Therapeutic Equivalency
D001688:Biological Products; D016568:Drugs, Generic; D011994:Recombinant Proteins